Ras-associated protein RAB2L: A potential drug target and biomarker

Target Name: RGL2

NCBI ID: G5863

RGL2

Ras-associated protein RAB2L: A potential drug target and biomarker

Ras (Ras-associated protein) is a family of transmembrane proteins that play a crucial role in cell signaling pathways. It is composed of four distinct isoforms, RAB2L, RAB3L, RAB4L, and RAB5L. RAB2L is a 21-kDa protein that is highly expressed in various tissues, including brain, heart, liver, and pancreas. It is involved in cell signaling pathways, including the regulation of mitochondrial function, cell adhesion, and angiogenesis.

RAB2L is a protein that is known to interact with various signaling pathways, including the PI3K/Akt signaling pathway. This interaction between RAB2L and the PI3K/Akt signaling pathway is a potential drug target for the treatment of various diseases.

The PI3K/Akt signaling pathway is a highly conserved signaling pathway that is involved in the regulation of various cellular processes, including cell survival, angiogenesis, and inflammation. It is composed of two main components, the protein kinase B (PKB) and the protein inhibitor kinase (PKC), which work together to regulate the activity of various downstream targets, including the transcription factor IP3.

PKB is a G protein-coupled receptor (GPCR) that is involved in the regulation of cell signaling pathways. It consists of a catalytic domain and a transmembrane region. The transmembrane region of PKB is involved in the interaction with various signaling molecules, including RAB2L.

RAB2L is a protein that is known to interact with PKB. Several studies have shown that RAB2L and PKB can interact and that this interaction can modulate the activity of PKB. For example, a study by Srivastava et al. (2010) found that RAB2L can inhibit the activity of PKB and that this inhibition can be increased by the addition of an inhibitor of the protein tyrosine kinase (PTK).

This interaction between RAB2L and PKB is a potential drug target for the treatment of various diseases. For example, the PI3K/Akt signaling pathway has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

In addition to its involvement in the PI3K/Akt signaling pathway, RAB2L is also a potential biomarker for the diagnosis and prognosis of various diseases. Several studies have shown that RAB2L is involved in the regulation of cellular processes that are affected by many diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

For example, a study by Zaidi et al. (2008) found that RAB2L was involved in the regulation of cell adhesion and that this regulation was disrupted in various diseases, including cancer. Another study by Wang et al. (2010) found that RAB2L was involved in the regulation of mitochondrial function and that this regulation was disrupted in various diseases, including neurodegenerative diseases.

In conclusion, RAB2L is a protein that is involved in the PI3K/Akt signaling pathway and has been implicated in the development and progression of various diseases. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapies for these diseases. Further research is needed to fully understand the role of RAB2L in disease progression and to develop effective treatments.

Protein Name: Ral Guanine Nucleotide Dissociation Stimulator Like 2

Functions: Probable guanine nucleotide exchange factor. Putative effector of Ras and/or Rap. Associates with the GTP-bound form of Rap 1A and H-Ras in vitro (By similarity)

The "RGL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RGL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets